Abstract: Compounds, systems, kits, methods, and/or apparatuses may be operative to reduce amyloid beta (A?) peptide in a patient, including a central nervous system (CNS) of the patient and/or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a A? displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds A? (for instance, A? peptide or non-plaque A?) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free A? peptide (for instance, A? monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and/or artificial processes, such as dialysis. Increased removal of the free A? peptide in the periphery may ultimately lead to less A? peptide in the CNS, which may decrease A? plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.

Abstract: Methods, apparatuses, and systems for determining patient dialysis profiles, for example, of peritoneal transport status or disease progression, are described. For example, in one embodiment, a method of determining a patient profile of a dialysis patient may include obtaining a volume of fluid associated with the dialysis patient, generating patient information via fluorescence analysis of the patient fluid, and determining the patient profile based on evaluating the patient information with a profile library, the patient profile comprising at least one of a peritoneal transport status classification or a disease progression. Other embodiments are described.

Abstract: Methods, apparatuses, and systems for determining patient dialysis profiles, for example, of peritoneal transport status or disease progression, are described. For example, in one embodiment, a method of determining a patient profile of a dialysis patient may include obtaining a volume of fluid associated with the dialysis patient, generating patient information via fluorescence analysis of the patient fluid, and determining the patient profile based on evaluating the patient information with a profile library, the patient profile comprising at least one of a peritoneal transport status classification or a disease progression. Other embodiments are described.

Abstract: Methods, apparatuses, and systems for determining a peritoneal transport status of a patient based on mass analyzing low volumes of peritoneal dialysis (PD) effluent to generate patient information that may be evaluated using PD effluent fingerprints to determine peritoneal transport characteristics of the patient are described. For example, in one embodiment, a method of determining a transport status of a dialysis patient may include obtaining a volume of peritoneal dialysis (PD) effluent of the dialysis patient, generating patient information via mass analysis of the volume of PD effluent, and determining patient profile information based on evaluating the patient information with a profile library, the patient profile information comprising a peritoneal transport status classification. Other embodiments are described.

Abstract: Methods, apparatuses, and systems for determining a peritoneal transport status of a patient based on mass analyzing low volumes of peritoneal dialysis (PD) effluent to generate patient information that may be evaluated using PD effluent fingerprints to determine peritoneal transport characteristics of the patient are described. For example, in one embodiment, a method of determining a transport status of a dialysis patient may include obtaining a volume of peritoneal dialysis (PD) effluent of the dialysis patient, generating patient information via mass analysis of the volume of PD effluent, and determining patient profile information based on evaluating the patient information with a profile library, the patient profile information comprising a peritoneal transport status classification. Other embodiments are described.

Abstract: An apparatus used in analyzing spent dialysate includes at least a first surface configured to accommodate a dialysate drain bag in a first predetermined position, and at least a second surface configured to accommodate a dialysate analysis device in a second predetermined position, such that when the dialysate drain bag is in the first predetermined position and the dialysate analysis device is in the second predetermined position, a light sensor of the dialysate analysis device is positioned to sense light passing through the dialysate drain bag.

Abstract: An apparatus used in analyzing spent dialysate includes at least a first surface configured to accommodate a dialysate drain bag in a first predetermined position, and at least a second surface configured to accommodate a dialysate analysis device in a second predetermined position, such that when the dialysate drain bag is in the first predetermined position and the dialysate analysis device is in the second predetermined position, a light sensor of the dialysate analysis device is positioned to sense light passing through the dialysate drain bag.

Abstract: An apparatus used in analyzing spent dialysate includes: at least one surface configured to accommodate a dialysate drain bag or drain line in a predetermined position; a light source positioned to emit light through the dialysate drain bag or drain line; and a light sensor positioned to sense light emitted by the light source through the dialysate drain bag or drain line.

Abstract: An apparatus used in analyzing spent dialysate includes: at least one surface configured to accommodate a dialysate drain bag or drain line in a predetermined position; a light source positioned to emit light through the dialysate drain bag or drain line; and a light sensor positioned to sense light emitted by the light source through the dialysate drain bag or drain line.

Abstract: A hemodialysis system includes: a hemodialysis machine configured to provide hemodialysis treatment to a patient, wherein the hemodialysis treatment includes circulating extracorporeal blood of the patient through an extracorporeal blood circuit; a first oxygen saturation sensor device configured to measure oxygen saturation corresponding to the extracorporeal blood of the patient in the extracorporeal blood circuit; a second oxygen saturation sensor device configured to measure oxygen saturation corresponding to blood flowing within the patient; and at least one controller configured to determine one or more oxygen saturation phase shift (OSPS) values or one or more transcutaneous travel time values corresponding to the patient based on oxygen saturation measurements from the first oxygen saturation sensor device and the second oxygen saturation sensor device.

Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.

Abstract: Compounds, systems, kits, methods, and/or apparatuses may be operative to reduce amyloid beta (A?) peptide in a patient, including a central nervous system (CNS) of the patient and/or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a A? displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds A? (for instance, A? peptide or non-plaque A?) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free A? peptide (for instance, A? monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and/or artificial processes, such as dialysis. Increased removal of the free A? peptide in the periphery may ultimately lead to less A? peptide in the CNS, which may decrease A? plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.

Abstract: Methods, apparatuses, and systems for determining patient dialysis profiles, for example, of peritoneal transport status or disease progression, are described. For example, in one embodiment, a method of determining a patient profile of a dialysis patient may include obtaining a volume of fluid associated with the dialysis patient, generating patient information via fluorescence analysis of the patient fluid, and determining the patient profile based on evaluating the patient information with a profile library, the patient profile comprising at least one of a peritoneal transport status classification or a disease progression. Other embodiments are described.

Abstract: An apparatus used in analyzing spent dialysate includes: at least one surface configured to accommodate a dialysate drain bag or drain line in a predetermined position; a light source positioned to emit light through the dialysate drain bag or drain line; and a light sensor positioned to sense light emitted by the light source through the dialysate drain bag or drain line.

Abstract: Techniques and devices for filtering dialysis fluids, such as dialysis effluent, are described. For example, a filter device may be configured to filter peritoneal dialysis (PD) effluent draining from a patient during a PD process. The filter devices may include filters configured to filter materials, such as human cells, microorganisms, and/or other components from PD effluent. For instance, a filter device may be configured to be installed in-line in a drain circuit of a PD system using conventional tubing. The captured materials may be analyzed or otherwise processed to determine health characteristics of a patient and/or to capture stem cells. Other embodiments are described.

Abstract: A hemodialysis system includes: a hemodialysis machine configured to provide hemodialysis treatment to a patient, wherein the hemodialysis treatment includes circulating extracorporeal blood of the patient through an extracorporeal blood circuit; a first oxygen saturation sensor device configured to measure oxygen saturation corresponding to the extracorporeal blood of the patient in the extracorporeal blood circuit; a second oxygen saturation sensor device configured to measure oxygen saturation corresponding to blood flowing within the patient; and at least one controller configured to determine one or more oxygen saturation phase shift (OSPS) values or one or more transcutaneous travel time values corresponding to the patient based on oxygen saturation measurements from the first oxygen saturation sensor device and the second oxygen saturation sensor device.

Abstract: methods, apparatuses, and systems for determining a peritoneal transport status of a patient based on mass analyzing low volumes of peritoneal dialysis (PD) effluent to generate patient information that may be evaluated using PD effluent fingerprints to determine peritoneal transport characteristics of the patient are described. For example, in one embodiment, a method of determining a transport status of a dialysis patient may include obtaining a volume of peritoneal dialysis (PD) effluent of the dialysis patient, generating patient information via mass analysis of the volume of PD effluent, and determining patient profile information based on evaluating the patient information with a profile library, the patient profile information comprising a peritoneal transport status classification. Other embodiments are described.

Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.